Clin Osteol 2010; 15(2): 48-50

The role of parathormone, calcitonin and sclerostin in the regulation of bone remodellingReview articles

V. Zikán

Bone is continuously remodelled to maintain its strength and mineral homeostasis. Osteocytes play an essential role in bone remo­ delling. The discovery of sclerostin, an osteocyte-derived inhibitor of Wnt signalling and bone formation, has provided new insights into communication networks between bone cells. In this review, we look at what is known about calciotropic hormones, parathyroid hormone and calcitonin, and osteocyte-derived sclerostin in the regulation of bone remodelling.

Keywords: bone remodelling, calcitonin, osteocytes, parathormone, sclerostin

Published: December 11, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zikán V. The role of parathormone, calcitonin and sclerostin in the regulation of bone remodelling. Osteologický bulletin. 2010;15(2):48-50.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zaidi M. Skeletal remodeling in health and disease. Nat Med 2007;13:791-801. Go to original source...
    2. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communica­ tion on and within bone controls bone remodeling. Bone 2009;44:1026-1033. Go to original source...
    3. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid Hormone (PTH) Induced Bone Gain is Blunted in SOST Overexpressing and Deficient Mice. J Bone Miner Res 2010;25:178-189. Go to original source...
    4. Rochefort GY, J^llu S, Benhamou CL. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int 2010 [v tisku]. Go to original source...
    5. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 2007;22: 1492-1501. Go to original source...
    6. Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res 2002; 17: 2068-2079. Go to original source...
    7. Kogianni G, Mann V, Noble BS. Apoptotic bodies convey activity capable of ini­ tiating osteoclastogenesis and localized bone destruction. J Bone Miner Res 2008;23:915-927. Go to original source...
    8. Fukumoto S. The role of bone in phosphate metabolism. Mol Cell Endocrinol 2009;310:63-70. Go to original source...
    9. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16:319-327. Go to original source...
    10. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280: 19883-19887. Go to original source...
    11. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:148-158. Go to original source...
    12. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 2009;44:275-286. Go to original source...
    13. Suva LJ. Sclerostin and the unloading of bone. J Bone Miner Res 2009;24: 1649-1650. Go to original source...
    14. Iwaniec UT, Wronski TJ, Liu J, Rivera MF, Arzaga RR, Hansen G, Brommage R. PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res 2007;22:394^02 Go to original source...
    15. Blahoš J. Kalcitonin a fosfokalciový metabolizmus, jeho fyziologický a klinický význam. Thomayerova sbírka, Avicenum, 1974; Praha.
    16. Woodrow JP, Sharpe CJ, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS. Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology 2006;147:4010^021. Go to original source...
    17. Hoff AO, Catala Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel RF. Increased bo­ ne mass is an unexpected phenotype associated with deletion of the calcitonin ge­ ne. J Clin Invest 2002;110:1849-1857. Go to original source...
    18. Schinke T, Liese S, Priemel M, Haberland M, Schilling AF, Catala-Lehnen P, Blicharski D, Rueger JM, Gagel RF, Emeson RB, Amling M. Decreased bone for­ mation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J Bone Miner Res 2004;19:2049-2056. Go to original source...
    19. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Gebre­ Medhin S, Galson DL, Zajac JD, Karsenty G. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 2004; 164:509-514. Go to original source...
    20. Huebner AK, Keller J, Catala-Lehnen P, Perkovic S, Streichert T, Emeson RB, Amling M, Schinke T. The role of calcitonin and alpha-calcitonin gene-related peptide in bone formation. Arch Biochem Biophys 2008;473:210-217. Go to original source...
    21. Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT, Walsh NC, Chia LY, Quinn JM, Martin TJ, Sims NA Calcitonin impairs the anabolic effect of PTH in young rats and stimulans expression of sclerostin by osteocytes. Bone 2010; (v tisku). Go to original source...
    22. Huebner AK, Schinke T, Priemel M, Schilling S, Schilling AF, Emeson RB, Rueger JM, Amling M. Calcitonin deficiency in mice progressively results in high bone turnover. J Bone Miner Res 2006;21:1924-1934. Go to original source...
    23. Richards JB, Kavvoura FK, Rivadeneira F, Styrkársdóttir U, Estrada K, Halldórsson BV, Hsu YH, Zillikens MC, Wilson SG, Mullin BH, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra BA, Pols HA, Sigurdsson G, Thorsteinsdottir U, Soranzo N, Williams FM, Zhou Y, Ralston SH, Thorleifsson G, van Duijn CM, Kiel DP, Stefansson K, Uitterlinden AG, Ioannidis JP, Spector TD; Genetic Factors for Osteoporosis Consortium. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med 2009;151:528-537. Go to original source...
    24. Chan A, van Bezooijen RL, Lowik CW. A new paradigm in the treatment of osteo­ porosis: Wnt pathway proteins and their antagonists. Curr Opin Investig Drugs 2007;8:293-298.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.